Lung Cancer Proteogenomics: New Era, New Insights
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Molecular Cancer Biology".
Deadline for manuscript submissions: 15 January 2025 | Viewed by 1867
Special Issue Editor
Special Issue Information
Dear Colleagues,
Lung cancer remains a major public health concern, constituting the second most prevalent malignancy and the leading cause of cancer-related mortality worldwide. Lung cancer incidence and outcomes vary depending on factors such as age, sex, ethnicity, smoking habits, environment, and socioeconomic status. Despite efforts to elucidate its molecular characteristics, it is still largely unknown why lung cancer is becoming the commonest and deadliest of cancers.
Integration of high-throughput molecular data originating from mass spectrometry (proteomics) to those of next-generation sequencing (genomics, transcriptomics) are currently paving the way towards designating molecular causes of cancer tumorigenesis. Proteogenomics is increasingly becoming a valuable instrument for biomedical research. This type of research is important in the lung cancer setting, not only for understanding its epidemiology, but also for studying effective therapeutic strategies in clinical applications.
For this Special Issue, we invite authors to contribute original research articles, method papers, as well as review articles that address recent achievements in proteogenomics associated with lung cancer research.
Potential topics include but are not limited to the following:
- Methods of genomic, transcriptomic, and proteomic data integration;
- Bioinformatic tools towards metagenomics and metaproteomics;
- Clinical lung cancer proteogenomics towards precision medicine;
- Lung cancer multi-omics.
Dr. Thanasis Anagnostopoulos
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- lung cancer
- genomic
- transcriptomic
- bioinformatic tools
- multi-omics
